RxDoctor Payments Data

Shannon Leon

Optometrist · San Antonio, TXNPI 1972986453

Payments from drug & device makers

$1,002in general payments, 2019–2025

Across 34 payments — averaging $29.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$341
  • Novartis$151
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$148
  • Aerie Pharmaceuticals, Inc.$81
  • Alcon$61
  • Bausch & Lomb Americas Inc.$46
  • plus $174 from 8 others

What the payments were for

  • Food & beverage$1,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,002 in reported general payments places this provider in the 50th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$45,888
Medicare patients
240
Services billed
639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine32$49,733
LumiganBimatoprost54$38,821
XiidraLifitegrast12$16,728
CombiganBrimonidine Tartrate/Timolol11$6,346
SimbrinzaBrinzolamide/Brimonidine Tart16$5,843
IlevroNepafenac11$4,167
Latanoprost280$3,255
Prednisolone Acetate49$2,884
Travoprost12$2,868
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat124$1,084
ValacyclovirValacyclovir Hcl22$1,066
Brimonidine Tartrate13$788
Dorzolamide Hcl37$734
Timolol Maleate35$191
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha15$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$341$94,90197 claims
Bausch & Lomb Americas Inc.Xiidra$46$16,72812 claims
AlconSimbrinza$61$5,84316 claims
NovartisIlevro$151$4,16711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,315 optometrist providers in Texas.

Other optometrist in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →